ALLOGENE THERAPEUTICS INC. - COMMON STOCK

Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting

13 Dec 2021 11:00:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology

13 Dec 2021 10:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting

01 Dec 2021 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences

12 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update  

04 Nov 2021 16:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials at the 63rd Annual Meeting of the American Society of Hematology

04 Nov 2021 09:05:39 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021

28 Oct 2021 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial

07 Oct 2021 16:15:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory Board

20 Sep 2021 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences

01 Sep 2021 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)

12 Aug 2021 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Second Quarter 2021 Financial Results

04 Aug 2021 16:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors

02 Aug 2021 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Second Quarter Financial Results on August 4, 2021

27 Jul 2021 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences

12 Jul 2021 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma

30 Jun 2021 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology

04 Jun 2021 09:00:01 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences

20 May 2021 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021

19 May 2021 16:51:33 By Nasdaq GlobeNewswire

Allogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021

12 May 2021 08:30:00 By Nasdaq GlobeNewswire